Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction

References

• NIH Consensus Conference. Impotence. NIH Consensus development panel on impotence. JAMA. 1993;270(38):83‐90.
   Google Scholar
• El-Sakka AI. Cardiovascular system as a ‘core’ of sexual life. Expert Opin Pharmacother. 2005;6(13):2223–2230.
   PubMed Web of Science ®Google Scholar
• Moreira Jr E, Brock D, Glasser G, et al. Help‐seeking behaviour for sexual problems: the global study of sexual attitudes and behaviors. Int J Clin Pract. 2005;59(38):6–16. .
   PubMedGoogle Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151(38):54–61.
   PubMedGoogle Scholar
• Mulhall J, King R, Glina S, et al. Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. J Sex Med. 2008;5(19):788–795.
   PubMedGoogle Scholar
• Malavige LS, Jayaratne SD, Kathriarachchi ST, et al. Erectile dysfunction is a strong predictor of poor quality of life in men with type 2 diabetes mellitus. Diabetic Med. 2014;31(79):699–706.
   PubMedGoogle Scholar
• Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151–157.
   PubMed Web of Science ®Google Scholar
• Omar YA, Younis SE, Ismail IY, et al. Testosterone level and endothelial dysfunction in patients with vasculogenic erectile dysfunction. Andrology. 2017;5(46):527–534.
   PubMedGoogle Scholar
• Mulhall JP, Giraldi A, Hackett G, et al. The 2018 revision to the process of care model for management of erectile dysfunction. J Sex Med. 2018;15(10):1434–1445.
   PubMed Web of Science ®Google Scholar
• Rosen RC. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res. 1999;11(2):59–70.
   PubMed Web of Science ®Google Scholar
• Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone. 2005;7(38):57–64.
   PubMedGoogle Scholar
• Eardley I, Dean J, Barnes T, et al. The sexual habits of British men and women over 40 years old. BJU Int. 2004;93(19):563–567.
   PubMedGoogle Scholar
• Conaglen HM, Conaglen JV. Couples’ reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24‐month follow‐up after a 6‐month free trial. J Sex Med. 2012;9(46):857–865.
   PubMedGoogle Scholar
• Sadovsky R, Brock GB, Gray M, et al. Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. J Am Acad Nurse Pract. 2011;23(79):320–330.
   PubMedGoogle Scholar
• Goldstein I, Kim E, Steers WD, et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med. 2007;4(38):166–175.
   PubMedGoogle Scholar
• Dean J, Rubio‐Aurioles E, McCabe M, et al. Integrating partners into erectile dysfunction treatment: improving the sexual experience for the couple. Int J Clin Pract. 2008;62(38):127–133.
   PubMedGoogle Scholar
• Chevret M, Jaudinot E, Sullivan K, et al. Impact of erectile dysfunction (ED) on sexual life of female partners: assessment with the Index of Sexual Life (ISL) questionnaire. J Sex Marital Ther. 2004;30(46):157–172.
   PubMedGoogle Scholar
• Smith WB, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long‐term adherence. Int J Clin Pract. 2013;67(8):768–780.
   PubMed Web of Science ®Google Scholar
• Hanson-Divers CHRIS, Jackson TINE, Lue SE, et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998;159(10):1541–1547.
   PubMedGoogle Scholar
• Althof SE. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res. 2002;14(38):S99–S104.
   PubMedGoogle Scholar
• Fusco F, Razzoli E, Imbimbo C, et al. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. BJU Int. 2010;105(12):1634–1639.
   PubMed Web of Science ®Google Scholar
• Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137(10):829–836.
   PubMedGoogle Scholar
• Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47–52.
   PubMedGoogle Scholar
• Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010;7(38):445–475.
   PubMedGoogle Scholar
• Hatzichristou D, Kirana PS, Banner L, et al. Diagnosing sexual dysfunction in men and women: sexual history taking and the role of symptom scales and questionnaires. J Sex Med. 2016;13(8):1166–1182.
   PubMed Web of Science ®Google Scholar
• Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Internal Med. 2011;171(20):1797–1803.
   PubMedGoogle Scholar
• Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(19):465–488.
   PubMedGoogle Scholar
• Moyad MA, Barada JH, Lue TF, et al. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin. 2004;31(2):259–273.
   PubMedGoogle Scholar
• Glina S, Sharlip ID, Hellstrom WJ. Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med. 2013;10(38):115–119.
   PubMedGoogle Scholar
• Donatucci CF, Wong DG, Giuliano F, et al. Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin. 2008;24(12):3383–3392.
   PubMed Web of Science ®Google Scholar
• Jiann BP, Yu CC, Su CC, et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res. 2006;18(2):146–149.
   PubMed Web of Science ®Google Scholar
• Ljunggren C, Hedelin H, Salomonsson K, et al. ED PHARMACOTHERAPY: giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long‐term treatment compliance. J Sex Med. 2008;5(2):469–475.
   PubMed Web of Science ®Google Scholar
• Albaugh J, Capelson R, Rwin Goldstein I. Health care clinicians in sexual health medicine: focus on erectile dysfunction. Urol Nurs. 2002;22(19):217.
   PubMedGoogle Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397–1404.
   PubMed Web of Science ®Google Scholar
• Perimenis P, Roumeguere T, Heidler H, et al. Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study. J Sex Med. 2009;6(38):257–267.
   PubMedGoogle Scholar
• Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(38):67–85.
   PubMedGoogle Scholar
• Nurnberg HG, Gelenberg A, Hargreave TB, et al. Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Am J Psychiatry. 2001;158(11):1926–1928.
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978–2984.
   PubMed Web of Science ®Google Scholar
• Schrader SM, Breitenstein MJ, Lowe BD. Erectile dysfunction: cutting off the nose to save the penis. J Sex Med. 2008;5(8):1932–1940.
   PubMed Web of Science ®Google Scholar
• Kupelian V, Araujo AB, Chiu GR, et al. Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Prev Med. 2010;50(1–2):19–25.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000;30(19):328–338.
   PubMedGoogle Scholar
• El-Sakka AI. Erectile dysfunction: association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med. 2007;4(79):1691–1700.
   PubMedGoogle Scholar
• Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol. 1994;140(11):1003–1008.
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18(19):405–410.
   PubMedGoogle Scholar
• Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56(2):302–306.
   PubMed Web of Science ®Google Scholar
• Maggi M, Buvat J, Corona G, et al. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med. 2013;10(46):661–677.
   PubMedGoogle Scholar
• Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010;7(19):1627–1656.
   PubMedGoogle Scholar
• Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol. 2012;97(10):1508–1516.
   Google Scholar
• Lee JC, Bénard F, Carrier S, et al. Do men with mild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population? BJU Int. 2011;107(79):956–960.
   PubMedGoogle Scholar
• Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment—a systematic review. Eur Urol. 2014;65(38):99–112.
   PubMedGoogle Scholar
• Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327–1351.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138–1144.
   PubMed Web of Science ®Google Scholar
• Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. Jama. 2013;310(17):1829–1836.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Akhras F, El‐Sakka AI, et al. Cardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency. Andrologia. 2011;43(38):1–8.
   PubMedGoogle Scholar
• Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65(38):115–123.
   PubMedGoogle Scholar
• El‐Sakka AI, Hassoba HM, Elbakry AM, et al. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005;2(2):235–240.
   PubMed Web of Science ®Google Scholar
• Beckman TJ, Abu-Lebdeh HS, Mynderse LA. Evaluation and medical management of erectile dysfunction. In: Mayo clinic proceedings. Vols. 81, No. 3, Elsevier; 2006 March. p. 385–390.
   Google Scholar
• Yassin A, AlRumaihi K, Alzubaidi R, et al. Testosterone, testosterone therapy and prostate cancer. Aging Male. 2019;22(4):219–227.
   PubMed Web of Science ®Google Scholar
• Patrick Selph J, Carson CC. Testosterone replacement therapy in men with prostate cancer: what is the evidence? Sex Med Rev. 2013;1(3):135–142.
   PubMedGoogle Scholar
• Sohn M, Hatzinger M, Goldstein I, et al. Standard operating procedures for vascular surgery in erectile dysfunction: revascularization and venous procedures. J Sex Med. 2013;10(38):172–179.
   PubMedGoogle Scholar
• Boddi V, Castellini G, Casale H, et al. An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology. 2015;3(10):909–918.
   PubMedGoogle Scholar
• Levine SB. The mental health professional treatment of erection problems. In: Handbook of clinical sexuality for mental health professionals. NY: Taylor and Francis, Routledge; 2016.
   Google Scholar
• Althof SE, Leiblum SR, Chevret‐Measson M, et al. Psychology: psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med. 2005;2(79):793–800.
   PubMedGoogle Scholar
• Althof SE, Needle RB. Psychological factors associated with male sexual dysfunction: screening and treatment for the urologist. Urol Clin. 2011;38(2):141–146.
   PubMed Web of Science ®Google Scholar
• Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. Bmj. 2000;321(7259):499–503.
   PubMed Web of Science ®Google Scholar
• Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(12):19–23.
   PubMed Web of Science ®Google Scholar
• Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641.
   PubMed Web of Science ®Google Scholar
• Hatzichristou D, Rosen RC, Derogatis LR, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med. 2010;7(1pt2):337–348.
   PubMedGoogle Scholar
• Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572–3588.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol. 2005;5(38):18.
   PubMedGoogle Scholar
• Jannini EA, Isidori AM, Gravina GL, et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med. 2009;6(9):2547–2560.
   PubMed Web of Science ®Google Scholar
• Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946–953. .
   PubMed Web of Science ®Google Scholar
• Moon KH, Ko YH, Kim SW, et al. Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial. J Sex Med. 2015;12(5):1194–1201.
   PubMed Web of Science ®Google Scholar
• Park HJ, Choi HK, Ahn TY, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med. 2010;7(8):2842–2850.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu D, Yang X, et al. The selectivity and potency of the new PDE 5 inhibitor TPN 729 MA. J Sex Med. 2013;10(11):2790–2797.
   PubMed Web of Science ®Google Scholar
• Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 August;Vol. 87(8):pp. 766–778. Elsevier.
   Web of Science ®Google Scholar
• Levine LA, Dimitriou RJ. Vaccum constriction and external erection devices in erectile dysfunction. Urologic Clini North Am. 2001;28(2):335–342.
   PubMed Web of Science ®Google Scholar
• Yuan J, Hoang AN, Romero CA, et al. Vacuum therapy in erectile dysfunction—science and clinical evidence. Int J Impot Res. 2010;22(19):211–219.
   PubMedGoogle Scholar
• Canguven O, Bailen J, Fredriksson W, et al. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med. 2009;6(9):2561–2567.
   PubMed Web of Science ®Google Scholar
• Deng H, Liu D, Mao X, et al. Phosphodiesterase-5 inhibitors and vacuum erection device for penile rehabilitation after laparoscopic nerve-preserving radical proctectomy for rectal cancer: A prospective controlled trial. Am J Men’s Health. 2017;11(3):641–646.
   PubMed Web of Science ®Google Scholar
• Rizk PJ, Krieger JR, Kohn TP, et al. Low-intensity shockwave therapy for erectile dysfunction. Sex Med Rev. 2018;6(4):624–630.
   PubMed Web of Science ®Google Scholar
• Palmieri A, Arcaniolo D, Palumbo F, et al. Low intensity shockwave therapy in combination with phosphodiesterase-5 inhibitors is an effective and safe treatment option in patients with vasculogenic ED who are PDE5i non-responders: a multicenter single-arm clinical trial. Int J Impot Res. 2020;1–7. DOI:10.1038/s41443-020-0332-7.
   PubMed Web of Science ®Google Scholar
• Peak TC, Anaissie J, Hellstrom WJ. Current perspectives on stem cell therapy for erectile dysfunction. Sex Med Rev. 2016;4(3):247–256.
   PubMedGoogle Scholar
• Yang J, Yu Z, Zhang Y, et al. Preconditioning of adipose‐derived stem cells by phosphodiesterase‐5 inhibition enhances therapeutic efficacy against diabetes‐induced erectile dysfunction. Andrology. 2020;8(1):231–240.
   PubMed Web of Science ®Google Scholar
• Kumar S, Ashraf M. Tadalafil, a phosphodiesterase inhibitor protects stem cells over longer period against hypoxia/reoxygenation injury through STAT3/PKG-I signaling. Stem Cells Dev. 2015;24(11):1332–1341.
   PubMed Web of Science ®Google Scholar
• Chahla J, Cinque ME, Piuzzi NS, et al. A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am. 2017;99(20):1769–1779. .
   PubMed Web of Science ®Google Scholar
• Chung EA. Review of current and emerging therapeutic options for erectile dysfunction. Med Sci (Basel). 2019;7(9):91. Published 2019 Aug 29.
   Google Scholar
• Borrelli F, Colalto C, Delfino DV, et al. Herbal dietary supplements for erectile dysfunction: a systematic review and meta-analysis. Drugs. 2018;78(6):643–673.
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Thirumavalavan N, Srivatsav A, et al. An analysis of popular online erectile dysfunction supplements. J Sex Med. 2019;16(6):843–852.
   PubMed Web of Science ®Google Scholar
• Hackett G, Kell P, Ralph D, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008;5(8):1841–1865.
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Hassan TA, Rienow J. 347 understanding the sexual habits of men taking medication for Erectile Dysfunction (ED): survey results from 7 countries. J Sex Med. 2017;14(38):S102.
   Google Scholar
• Rajagopalan P, Mazzu A, Xia C, et al. Effect of high‐fat breakfast and moderate‐fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase‐5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43(46):260–267.
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Burri A, et al. The safety and efficacy of avanafil, a new 2nd generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf. 2016;15(2):237–247.
   PubMed Web of Science ®Google Scholar
• Jung J, Choi S, Cho SH, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single-and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010;32(79):1178–1187.
   PubMedGoogle Scholar
• Goldstein I, McCullough AR, Jones LA, et al. A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(19):1122–1133.
   PubMedGoogle Scholar
• Damle B, Duczynski G, Jeffers BW, et al. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014;36(2):236–244.
   PubMed Web of Science ®Google Scholar
• Capogrosso P, Ventimiglia E, Boeri L, et al. Time of onset of vardenafil orodispersible tablet in a real-life setting–looking beyond randomized clinical trials. Expert Rev Clin Pharmacol. 2017;10(46):339–344.
   PubMedGoogle Scholar
• Heinig R, Weimann B, Dietrich H, et al. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil. Clin Drug Investig. 2011;31(38):27–41.
   PubMedGoogle Scholar
• Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(38):130–171.
   PubMedGoogle Scholar
• Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7(38):524–540.
   PubMedGoogle Scholar
• Forgue ST, Phillips DL, Bedding AW, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007;63(38):24–35.
   PubMedGoogle Scholar
• Moncada I, Jara J, Subirá D, et al. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol. 2004;46(46):357–361.
   PubMedGoogle Scholar
• McMahon C. Comparison of efficacy, safety, and tolerability of on‐demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2(46):415–427.
   PubMedGoogle Scholar
• Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50(2):351–359.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004;45(46):339–345.
   PubMedGoogle Scholar
• Seftel AD, Wilson SK, Knapp PM, et al. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. J Urol. 2004;172(2):652–657.
   PubMed Web of Science ®Google Scholar
• Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 Part 1):1332–1336.
   PubMed Web of Science ®Google Scholar
• Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol. 2005;47(38):87–91.
   PubMedGoogle Scholar
• Vignozzi L, Filippi S, Morelli A, et al. Basic Science: effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006;3(46):419–431.
   PubMedGoogle Scholar
• El‐Sakka AI, Sayed HM, Tayeb KA. Type 2 diabetes‐associated androgen alteration in patients with erectile dysfunction. Int JAndrology. 2008;31(79):602–608.
   PubMedGoogle Scholar
• El‐Sakka AI. Erectile dysfunction, depression, and ischemic heart disease: does the existence of one component of this triad necessitate inquiring the other two?(CME). J Sex Med. 2011;8(19):937–940.
   PubMedGoogle Scholar
• Abdelhamid AA, Sherief MH, Nemr NA, et al. Homocysteine, insulin‐like growth factor one and oestrogen levels in patients with erectile dysfunction‐associated chronic hepatitis C virus infection. Andrologia. 2018;50(10):e13116.
   PubMed Web of Science ®Google Scholar
• Romeo JH, Seftel AD, Madhun ZT, et al. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163(3):788–791.
   PubMed Web of Science ®Google Scholar
• Jackson G, Montorsi P, Adams MA, et al. Cardiovascular aspects of sexual medicine. J Sex Med. 2010;7(19):1608–1626.
   PubMedGoogle Scholar
• Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the “tip of the iceberg” of a systemic vascular disorder? European Urology. 2003;44:352–354.
   Web of Science ®Google Scholar
• DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel. Am J Cardiol. 2000;86(2):62–68.
   Web of Science ®Google Scholar
• Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96(12):85–93.
   Web of Science ®Google Scholar
• Jackson G, Rosen RC, Kloner RA, et al. REPORT: the Second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3(38):28–36.
   PubMedGoogle Scholar
• Otero JR, Gómez BG, Polo JM, et al. Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use. Urology. 2014;83(79):1334–1338.
   PubMedGoogle Scholar
• Carvalheira AA, Pereira NM, Maroco J, et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med. 2012;9(9):2361–2369.
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Creanga DL, Stecher VJ. Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mg. Int J Gen Med. 2013;6:849.
   PubMedGoogle Scholar
• El-Sakka AI. Middle East cultural challenges and the treatment of sexual problems in men. In: Cultural differences and the practice of sexual medicine. Cham: Springer; 2020. p. 135–148.
   Google Scholar
• Ghanem H, El-Sakka A. Sex and sexual dysfunctions in the Middle Eastern culture. Sexual Health [Four volumes](Sex, Love, and Psychology). 2007;3:279–296.
   Google Scholar